homepage-top-section

The drug is intended to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) in

The biopharmaceutical company stated that the dormant vaccine manufacturing site would add new capabilities to its medicine portfolio of Canadian and US companies. It is expected to allow

The US regulator has accepted the company’s supplemental new drug application (sNDA) for Evrysdi to treat SMA in pre-symptomatic babies, aged below two months. Evrysdi is a survival

As part of the collaboration, the US-based company will use its Library of Libraries for the discovery of new antibodies against Artisan Bio’s immunotherapy targets. Meanwhile, Artisan will

The acquisition will help accelerate the company’s growth and establish a footprint in the menopause market. Previously, Amyris announced plans to establish a new consumer brand to offer

APS03118 is a second generation selective rearranged during transfection (RET) inhibitor that targets patients suffering with non-small cell lung cancer, breast cancer, ovarian cancer, thyroid cancer, colorectal cancer,

Senhwa Biosciences acting CEO Mei-Hui Kuo said: “We are pleased to receive ODD for Silmitasertib for the treatment of Biliary Tract Cancer, a rare, malignant disease for which

The date for the FDA decision is on 19 September 2022. The sBLA is backed by results from a randomized, multicenter Phase 3 study. The study investigated Libtayo

Jyseleca is indicated for usage in moderately to severely active UC adult patients, with insufficient, lost response to or were not tolerant to either standard treatment or a